Oncolytic Virus CDMO Services Market Overview
The global Oncolytic Virus CDMO Services market was valued at USD 2.4 billion in 2024 and is expected to grow from USD 2.6 billion in 2025 to USD 6.5 billion by 2035, registering a CAGR of 9.6% during the forecast period from 2025 to 2035. The market is being driven by increasing demand for innovative cancer therapies, growing investment in oncolytic virus research, advances in viral engineering, and the expanding need for specialized contract development and manufacturing capabilities.
North America is expected to remain the leading regional market, with its value projected to increase from USD 800 million in 2024 to approximately USD 2.097 billion by 2035. Europe is also expected to maintain a significant position, while Asia Pacific is anticipated to register strong growth as biotechnology investments, healthcare expenditure, and advanced therapeutic development expand.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=622551
Key Companies in the Oncolytic Virus CDMO Services Market
Merck
Iovance Biotherapeutics
Eli Lilly
Inovio Pharmaceuticals
Oncolytics Biotech
Genmab
Bristol Myers Squibb
SillaJen
Vaxart
Abpro Corporation
CureVac
Viralytics
Amgen
GSK
Transgene
Celltrion
The Oncolytic Virus CDMO Services Market is benefiting from the growing number of oncolytic virus development programs and the increasing complexity of viral therapeutic manufacturing. Pharmaceutical and biotechnology companies are increasingly outsourcing specialized process development, manufacturing, quality control, regulatory support, and clinical supply management to experienced CDMOs. Advances in virus engineering, viral vector development, delivery systems, and scalable manufacturing are further creating opportunities across the market.
The market is segmented by service type, therapeutic area, technology platform, end user, and region. Service types include Process Development, Manufacturing, Quality Control, Regulatory Support, and Clinical Supply Management. Therapeutic areas include Cancer, Infectious Diseases, and Autoimmune Disorders. Technology platforms comprise Virus Engineering, Viral Vector Development, and Delivery Systems, while end users include Pharmaceutical Companies, Biotechnology Companies, and Academic Research Institutes.
Recent Developments and Market Trends:
Increasing demand for innovative cancer therapies is supporting the expansion of specialized oncolytic virus CDMO services.
Personalized oncolytic virus therapies are gaining attention as oncology moves toward more tailored treatment strategies.
Advances in viral engineering are improving the development and scalability of oncolytic virus manufacturing processes.
Growing pharmaceutical and biotechnology investment is increasing demand for outsourced development and manufacturing capabilities.
Strategic collaborations between biopharmaceutical companies and CDMOs are helping accelerate oncolytic virus development programs.
AI-driven analytics and process optimization are creating opportunities to improve manufacturing efficiency and product yields.
Expansion of CDMO capacity is supporting the transition of oncolytic virus candidates from research and development into clinical-stage production.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast of the global Oncolytic Virus CDMO Services Market.
Analyze market segmentation by service type, therapeutic area, technology platform, end user, and region.
Evaluate growth opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Identify leading companies and assess the competitive landscape of the oncolytic virus CDMO services industry.
Examine the factors driving demand for specialized viral therapeutic development and manufacturing.
Understand emerging opportunities associated with personalized therapies, viral engineering, and advanced delivery systems.
Assess the impact of biotechnology investment, strategic partnerships, and manufacturing technology advancements on future market development.
Future Outlook:
The Oncolytic Virus CDMO Services Market is expected to maintain strong growth through 2035 as pharmaceutical and biotechnology companies expand their pipelines of innovative viral therapies. Increasing cancer prevalence, advances in viral engineering, demand for personalized oncology treatments, and the growing preference for specialized outsourcing are expected to create significant opportunities. Continued investment in scalable manufacturing, process optimization, quality control, and regulatory capabilities should further strengthen the role of CDMOs in bringing oncolytic virus therapies from development to clinical and commercial stages.
➤➤Explore Our Latest Related Reports:
